HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzales, A. E. Articles by Lopez-Urbina, M. T. Search for Related Content PubMed PubMed Citation Articles by Gonzales, A. E. Articles by Lopez-Urbina, M. T.

Effective, Single-Dose Treatment of Procine Cysticercosis with Oxfendazole

The pig is a vital link in the transmission cycle of Taenia solium, the cestode responsible for human-porcine cysticercosis. Infected pigs also represent an important source of economic loss to farmers in developing countries. Past efforts to find an adequate therapeutic regimen to treat this parasitic disease in swine have failed because of low efficacy, high cost, side effects, or the need for multiple doses. In this randomized, no treatment-controlled study, the efficacy and safety of oxfendazole and praziquantel for the treatment of porcine cysticercosis were evaluated in 16 naturally infected pigs. Four groups of four pigs were treated with oxfendazole, praziquantel, oxfendazole plus praziquantel, or untreated. The pigs were humanely killed 12 weeks post-treatment, the number of cysts was counted, and parasite viability was assessed by cyst evagination. No detectable side effects were seen in any of the pigs. Praziquantel treatment alone appeared to reduce the number of cysts, but did not decrease the viability of the remaining parasites. Treatment with oxfendazole alone or oxfendazole plus praziquantel killed all of the parasites, and left only microcalcifications in the meat. Oxfendazole provides, for the first time, a practical, effective, inexpensive, and single-dose therapy for porcine cysticercosis.

This article has been cited by other articles:

				T. E. Nash, G. Singh, A. C. White, V. Rajshekhar, J. A. Loeb, J. V. Proano, O. M. Takayanagui, A. E. Gonzalez, J. A. Butman, C. DeGiorgio, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology, October 10, 2006; 67(7): 1120 - 1127. [Abstract] [Full Text] [PDF]

				H. H Garcia, A. E Gonzalez, V. C W Tsang, R. H Gilman, and for the Cysticerocosis Working Group in Peru Neurocysticercosis: some of the essentials Practical Neurology, October 1, 2006; 6(5): 288 - 297. [Full Text] [PDF]

				H. H. GARCIA, A. E. GONZALEZ, R. H. GILMAN, L. H. MOULTON, M. VERASTEGUI, S. RODRIGUEZ, C. GAVIDIA, V. C. W. TSANG, and THE CYSTICERCOSIS WORKING GROUP IN PERU COMBINED HUMAN AND PORCINE MASS CHEMOTHERAPY FOR THE CONTROL OF T. SOLIUM. Am J Trop Med Hyg, May 1, 2006; 74(5): 850 - 855. [Abstract] [Full Text] [PDF]

				I. Rojas-Flores, S. Kumar, H. H. Garcia, R. H. Gilman, and A. E. Gonzalez A Trial of Antiparasitic Treatment for Cerebral Cysticercosis N. Engl. J. Med., April 15, 2004; 350(16): 1686 - 1687. [Full Text] [PDF]

				H. H. Garcia, E. J. Pretell, R. H. Gilman, S. M. Martinez, L. H. Moulton, O. H. Del Brutto, G. Herrera, C. A.W. Evans, A. E. Gonzalez, and the Cysticercosis Working Group in Peru A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis N. Engl. J. Med., January 15, 2004; 350(3): 249 - 258. [Abstract] [Full Text] [PDF]